Valsartan

Pre-clinicalWithdrawn

0 views this week 0 watching💤 Quiet

Interest: 18/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cerebrovascular Accident

Conditions

Cerebrovascular Accident

Trial Timeline

Aug 1, 2007 → —

NCT ID

NCT00627991

About Valsartan

Valsartan is a pre-clinical stage product being developed by Novartis for Cerebrovascular Accident. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00627991. Target conditions include Cerebrovascular Accident.

What happened to similar drugs?

5 of 7 similar drugs in Cerebrovascular Accident were approved

Approved (5) Terminated (1) Active (1)

✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved

✅ticagrelor + ASA + Placebo+ASAAstraZenecaApproved

✅AtorvastatinPfizerApproved

✅Botulinum toxin type A + PlaceboIpsenApproved

✅Atorvastatin 20mgBrain BiotechApproved

🔄donepezil hclEisaiPhase 3

❌AbciximabEli LillyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01541189	Approved	Completed	Feb 1, 2012	Jan 1, 2013	Hypertension
NCT00627991	Pre-clinical	Withdrawn	Aug 1, 2007	—	Cerebrovascular Accident
NCT00550095	Approved	Completed	Jun 1, 2007	Nov 1, 2009	Microalbuminuria
NCT00457626	Phase 3	Completed	Apr 9, 2007	May 25, 2009	Hypertension
NCT01425411	Approved	Completed	Nov 1, 2006	Nov 1, 2008	Hypertension
NCT00589732	Approved	Completed	Sep 1, 2006	Dec 1, 2009	Coronary Artery Disease
NCT00415883	Phase 1	Completed	Jul 1, 2006	—	Healthy
NCT00394745	Phase 3	Completed	Nov 1, 2005	Jun 1, 2007	Hypertension
NCT00343499	Approved	Terminated	Nov 1, 2004	Jul 1, 2007	Atrial Fibrillation
NCT00170924	Approved	Completed	Aug 1, 2004	Jun 1, 2006	Diastolic Dysfunction
NCT00171353	Approved	Completed	Jul 1, 2004	Sep 1, 2005	Hypertension
NCT00333489	Approved	Completed	Mar 1, 2004	Apr 1, 2005	Hypertension
NCT00171119	Approved	Terminated	Jan 1, 2004	—	Hypertension
NCT00171028	Phase 3	Completed	Dec 1, 2003	Nov 1, 2006	Hypertension
NCT00241137	Phase 3	Completed	Sep 1, 2003	Jan 1, 2005	Hypertension
NCT00241098	Approved	Completed	May 1, 2003	Jun 1, 2005	Hypertension
NCT00171041	Phase 3	Completed	Dec 1, 2002	Mar 1, 2006	Hypertension
NCT00171106	Approved	Completed	Dec 1, 2002	Feb 1, 2008	Diastolic Dysfunction, Symptomatic Heart Failure
NCT00241150	Approved	Completed	Nov 1, 2002	Jan 1, 2005	Hypertension
NCT00241085	Approved	Completed	Nov 1, 2002	Aug 1, 2005	PROTEINURIA

Competing Products

14 competing products in Cerebrovascular Accident

See all competitors

Product	Company	Stage	Hype Score
YM872 (zonampanel)	Astellas Pharma	Phase 2	35
donepezil hcl	Eisai	Phase 3	40
Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride	Eisai	Approved	43
ONO-2506	Ono Pharmaceutical	Phase 2/3	30
Abciximab	Eli Lilly	Phase 3	32
atomoxetine + Stimulants	Eli Lilly	Pre-clinical	26
ticagrelor + ASA + Placebo+ASA	AstraZeneca	Approved	43
Atorvastatin	Pfizer	Approved	43
Rivaroxaban	Bayer	Pre-clinical	19
Darolutamide (BAY1841788) + Enzalutamide	Bayer	Phase 1	26
Botulinum toxin type A + Placebo	Ipsen	Approved	40
Atorvastatin 20mg	Brain Biotech	Approved	40
Autologous bone marrow mononuclear cell transplantation	Brain Biotech	Phase 1	11
Roflumilast Oral Tablet	Brain Biotech	Phase 2	25